Impact of Contralateral Systematic Biopsy Omission on Nomogram-based Surgical Planning in Prostate Cancer: A Multicentre Study (Cobra)
The COBRA study demonstrates that omitting contralateral systematic biopsy does not significantly alter lymph node invasion predictions for extended pelvic lymph node dissection planning but systematically overestimates extracapsular extension and seminal vesicle invasion risks, rendering ipsilateral-only data unsuitable for nerve-sparing decisions without model recalibration.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Before a surgeon can plan the removal of a prostate gland, they must first map the hidden terrain of the disease. Prostate cancer does not always stay in one place; it can spread to nearby lymph nodes or push through the organ's outer capsule. To decide how extensive the surgery should be, doctors rely on risk calculators. These are mathematical tools that take information from a patient's blood tests, magnetic resonance imaging scans, and tissue samples to predict the odds of the cancer spreading. For decades, the standard way to gather tissue samples involved taking many small needles from both the left and right sides of the prostate, a procedure known as a systematic biopsy. However, the medical world has recently shifted toward a more targeted approach. With the help of detailed MRI scans, doctors can now aim needles directly at suspicious spots and sample the tissue immediately around them, often skipping the opposite side of the gland entirely if no issues are visible there. This change reduces the physical burden on the patient, but it leaves a critical question unanswered: if a doctor skips the tissue samples from the healthy-looking side, will the risk calculators still give an accurate map for the surgery?
A large study involving nearly a thousand men across six European centers set out to answer this question. The researchers, led by Francesco Sanguedolce and colleagues, looked at patients who had undergone the modern targeted biopsy followed by surgery. They wanted to see if the risk predictions changed when they fed the calculators only the data from the side with the tumor versus the data from both sides. The study focused on two main types of surgical decisions. The first was whether to remove lymph nodes, a procedure that carries its own risks and is only recommended if the chance of cancer spreading there is high enough. The second was whether to spare the delicate nerves that control erections, a decision that depends on how likely the cancer is to have pushed outside the prostate or invaded nearby structures.
The results revealed a clear split in how these different calculators react to missing data. When the team tested the model used to predict lymph node spread, they found that skipping the samples from the opposite side made almost no difference. Whether the doctors used the full set of tissue samples or just the ones from the side with the tumor, the risk estimates remained nearly identical. In the vast majority of cases, the decision to remove lymph nodes or leave them alone stayed the same. Even in patients with tumors on both sides of the prostate, the simplified data led to the same surgical recommendations as the complete data. This suggests that for planning lymph node removal, the modern, less invasive biopsy strategy is safe to use without needing to adjust the risk tools.
However, the story was different for the second type of decision regarding nerve-sparing surgery. When the researchers applied the same simplified data to the models that predict whether cancer has spread outside the prostate or into the seminal vesicles, the results shifted systematically. The calculators, fed only with data from the tumor side, consistently predicted a higher risk of spread than when they were fed the full picture. This overestimation was significant enough to change the surgical plan for many patients, pushing them into a higher-risk category where surgeons might choose to remove the nerves to ensure the cancer is gone. Yet, when the researchers checked the actual tissue removed during surgery, they found that most of these patients did not actually have the spread that the simplified data had predicted. In one specific instance involving the seminal vesicles, the model flagged over a hundred patients as high risk based on the limited data, but only four of them actually had the disease confirmed in the final pathology report.
The study concludes that while the new, less invasive biopsy methods are excellent for deciding whether to remove lymph nodes, they cannot be used interchangeably with the old methods for nerve-sparing decisions without caution. The risk calculators for nerve preservation were built on the assumption that doctors had samples from both sides of the prostate. When that assumption is broken, the tools tend to sound a false alarm, suggesting the cancer is more aggressive than it truly is. For surgeons, this means that if they choose to skip the biopsy on the healthy side, they must be aware that the standard risk numbers for nerve sparing will likely look worse than reality. The solution is not to stop using the modern biopsy, but to understand that the map it provides needs to be read differently depending on which part of the surgery is being planned.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.